阿替普酶治疗急性缺血性脑卒中的有效性分析与研究

Effective Analysis and Study of Alteplase in Acute Ischemic Stroke

目的探讨阿替普酶治疗急性缺血性脑卒中的有效性。方法选择2016年1月—2017年1月40例急性缺血性脑卒中患者分组。对照组采用小剂量阿替普酶治疗,观察组用常规剂量阿替普酶治疗。比较两组急性缺血性脑卒中治疗有效性;治疗3个月死亡率;干预前后患者NHISS评分、MRS评分;不良反应发生率。结果观察组急性缺血性脑卒中治疗有效性高于对照组(P<0.05);观察组治疗3个月死亡率和对照组无显著差异(P>0.05);干预前两组NHISS评分、MRS评分相近(P>0.05);干预后观察组NHISS评分、MRS评分优于对照组(P<0.05)。两组不良反应发生率无显著差异(P>0.05)。结论阿替普酶治疗急性缺血性脑卒中的有效性高,其中,常规剂量治疗效果优于小剂量治疗效果,可更好改善患者预后和神经功能,且不增加不良事件和死亡率,值得推广。

Objective To investigate the effectiveness of alteplase in the treatment of acute ischemic stroke. Methods From January 2016 to January 2017, 40 patients with acute ischemic stroke were divided into groups. The control group was treated with low-dose alteplase, and the observation group was treated with conventional alteplase. The effectiveness of the treatment of acute ischemic stroke was compared between two groups; the mortality rate at 3 months; the scores of NHISS and MRS before and after the intervention; the incidence of adverse reactions were compared. Results The effective rate of treatment of acute ischemic stroke in the observation group was higher than that of the control group （P 〈 0.05）. There was no significant difference between the observation group and the control group in the 3-month mortality rate （P 〉 0.05）. There were no signifcant difference in scores of NHISS, MRS between two group before treatment （P 〉 0.05）,After intervention, the NHISS score and MRS score of the observation group were better than those of the control group （P 〈 0.05）. No signifcant difference in the incidence of adverse reactions between the two groups（P 〉 0.05）. Conclusion Altiplase is effective in treating acute ischemic stroke. Among them, the effect of conventional dose is better than that of low dose, which can improve the prognosis and neurological function of patients without any adverse event and mortality. Worth promoting.